View Older Stories View More Recent Stories

Feb 19, 2021 07:05AM Ionis to present at upcoming investor conferences
Feb 11, 2021 07:05AM Ionis to hold 2020 financial results webcast
Jan 8, 2021 07:31AM Biogen (BIIB) Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA in Patients Treated With Zolgensma
Jan 8, 2021 07:30AM Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
Jan 8, 2021 07:30AM Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
Jan 7, 2021 05:30PM Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
Jan 5, 2021 07:05AM Ionis to present at 39th Annual J.P. Morgan Healthcare Conference
Dec 17, 2020 06:30PM Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
Dec 8, 2020 09:15PM Ionis highlights achievements, commercial strategy and technology advancements at Investor Day
Dec 2, 2020 07:05AM Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference
Dec 1, 2020 05:10PM Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
Dec 1, 2020 07:05AM Ionis to hold virtual investor day event
Nov 30, 2020 05:15PM Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
Nov 23, 2020 05:18PM Ionis (IONS) announces AstraZeneca (AZN) has licensed ION455, an investigational antisense medicine being developed as potential treatment for NASH
Nov 23, 2020 05:15PM Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
Nov 13, 2020 07:05AM Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020
Nov 12, 2020 07:05AM Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020
Nov 10, 2020 07:05AM Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference
Nov 9, 2020 07:05AM Ionis to present at upcoming virtual investor conferences
Nov 6, 2020 03:00AM Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung Heroes
Nov 4, 2020 07:00AM Ionis reports third quarter 2020 financial results and recent business achievements
Nov 4, 2020 06:17AM Ionis Pharmaceuticals (IONS) Reports Pfizer (PFE) to Begin Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)
Nov 3, 2020 06:00PM Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
Oct 30, 2020 07:00AM Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
Oct 22, 2020 07:05AM Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
Oct 21, 2020 07:05AM Ionis to hold third quarter 2020 financial results webcast
Oct 15, 2020 07:11AM Ionis Pharmaceuticals (IONS) antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
Oct 15, 2020 07:05AM Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
Oct 13, 2020 07:05AM Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
Oct 13, 2020 07:05AM /C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./
Oct 12, 2020 09:00AM Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
Oct 1, 2020 04:05PM Ionis Chief Scientific Officer Frank Bennett receives Lifetime Achievement Award from Oligonucleotide Therapeutics Society
Oct 1, 2020 06:20AM Ionis Pharmaceuticals (IONS), Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics
Oct 1, 2020 06:00AM Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics
Sep 30, 2020 04:05PM Ionis Pharmaceuticals (IONS) treatment for Alexander disease receives orphan drug designation from U.S. FDA
Sep 30, 2020 04:05PM Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA
Sep 18, 2020 06:17AM Akcea Therapeutics (AKCA) Announces WAYLIVRA to Be Available on the NHS in England
Sep 18, 2020 03:00AM WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England
Sep 3, 2020 07:05AM Ionis to present at upcoming virtual investor conferences
Sep 2, 2020 05:13PM Ionis Pharmaceuticals (IONS) announces NEJM publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema
Sep 2, 2020 05:10PM New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema
Aug 31, 2020 07:21AM Ionis Pharmaceuticals (IONS) to acquire remaining stake in Akcea Therapeutics (AKCA) for $18.15/sh
Aug 31, 2020 06:55AM Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
Aug 31, 2020 06:01AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Highlight Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx))
Aug 31, 2020 06:00AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Present Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx)
Aug 29, 2020 04:00AM Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
Aug 29, 2020 03:30AM Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
Aug 26, 2020 07:05AM Ionis Pharmaceuticals to hold cardio-renal franchise webcast
Aug 24, 2020 07:00AM Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
Aug 18, 2020 07:07AM Akcea Therapeutics (AKCA), Ionis (IONS) to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
View More Recent Stories View Older Stories